參考文獻 |
1. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92. doi:10.1016/j.schres.2010.11.020 2. Owen, M.J., A. Sawa, and P.B. Mortensen, Schizophrenia. Lancet, 2016. 388(10039): p. 86-97. 3. Birchwood, M., Todd, P., & Jackson, C. (1998). Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl, 172(33), 53-59. 4. Rapoport, J. L., Giedd, J. N., & Gogtay, N. (2012). Neurodevelopmental model of schizophrenia:update 2012. Molecular psychiatry, 17(12), 1228-1238. 5. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:1. 6. Haddad P, Brain C, Scott J. Nonadherence with anti- psychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43. 7. Berwaerts J, et al. JAMA Psychiatry. 2015;72(8):830-839. 8. Leucht C et al Schizophr Res 2011;127:83–92 9. Robinson D, et al. Arch Gen Psychiatry. 1999;56(3):241-247. 10. 世界衛生組織,2018 11. 美國精神科醫學會,2013. 12. 衛生福利部心理衛生專輯:認識精神疾病 |